$0.07
(1.34%)
Create an alert
Stocks and Shares ISACingulate Inc. is a biopharmaceutical company. The Company offers Precision Timed Release (PTR), which is a drug delivery platform technology to build and advance a pipeline of pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety. Its PTR platform incorporates an erosion barrier layer (EBL) designed to allow for the release of drug substances at specific, pre-defined time intervals. It develops stimulant medications which include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of ADHD across all three patient segments: children (aged 6 -12), adolescents (aged 13-17), and adults (aged 18+). It also develops CTx-2103 (buspirone), for the treatment of anxiety.
Company Information
About this company
Key people
John A. Roberts
Chairman of the Board
Zhanpeng Jiang
Independent Director
Bryan Lawrence
Independent Director
Shane J. Schaffer
Chief Executive Officer
Raul R. Silva
Co-Founder, Executive Vice President, Chief Science Officer
Matthew N. Brams
Co-Founder, Executive Vice President, Chief Medical Officer
Jennifer L. Callahan
Chief Financial Officer
Nilay Patel
Chief Legal Officer
Peter J. Werth
Director
Jeffrey S. Ervin
Independent Director
Jeff Hargroves
Independent Director
Click to see more
Key facts
- Shares in issue12.25m
- EPICCING
- ISINUS17248W3034
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$65.30m
- Employees14
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.